- MHRA Drug Safety Update: Valproate use in men: as a precaution, men and their partners should use effective contraception (Sept 2024)
- MHRA Drug Safety Update: Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age (Jan 2024)
- MHRA National Patient Safety Alert: Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients (Nov 2023)
- MHRA Guide for healthcare professionals: Information on the use of valproate in all patients
- Location of the Valproate referral form in Ardens
- Annual Risk Acknowledgement Form (ARAF) for females (for completion by specialists)
- Risk Acknowledgement Form for male patients starting valproate (for completion by specialists)
Patient resources
- MHRA: Advice for male patients on valproate to use contraception
- MHRA: Patient guide: What you need to know about valproate
- NHSE: Is valproate the right epilepsy medication for me?
- NHSE: Bipolar disorder: Is valproate the right medication for me?
- Epilepsy Action: New rules for taking sodium valproate
- Epilepsy Action: Sodium valproate medicines and risks in pregnancy
- Epilepsy Society: Sodium valproate
- Epilepsy Society: New prescribing practices for valproate
- Young Epilepsy: New safety measures for valproate
The Yellow Card Scheme is used for the reporting of suspected adverse drug reactions (side effects) to any medicines and medical devices. It also includes any suspected defective or counterfeit medicines and medical devices.
Yellow Card | Making medicines and medical devices safer (mhra.gov.uk)